GreenBank Capital Portfolio Company CodiKoat Delivers Revolutionary Biosafety Product and Enters Into Partnerships
GreenBank Capital Inc. announced its portfolio company CodiKoat developed a revolutionary biosafety product that addresses public touchscreen health hazards. CodiKoat partnered with UK firms BDK and Keeling & Walker to produce a transparent adhesive film that provides antimicrobial protection against harmful viruses and bacteria. This self-cleaning solution has shown efficacy in laboratory tests, capable of killing 90% of human coronavirus in 2 seconds. CEO Terry Pullen highlighted the significant market opportunity and effective recognition of this innovative product.
- CodiKoat's product demonstrates effectiveness, killing 90% of human coronavirus in 2 seconds and over 99% in 10 seconds.
- Successful partnerships with established manufacturers BDK and Keeling & Walker enhance production capabilities.
- The product is self-cleaning and durable, reducing cleaning resource drain for businesses using touchscreen devices.
- None.
Antimicrobial innovation helps solve significant public touchscreen health hazard
CodiKoat partners with MedTech firm BDK and raw metal company Keeling & Walker
TORONTO, ON / ACCESSWIRE / March 28, 2022 / GreenBank Capital Inc. ("GreenBank" or "the Company"), the next-generation merchant bank, is pleased to announce that biotech portfolio company CodiKoat (https://codikoat.com/) has delivered a groundbreaking biosafety product to solve a significant public touchscreen health hazard. Furthermore, in support of delivering this groundbreaking public health solution, the Cambridge based biotech firm has entered into partnerships with two market-leading UK-based manufacturers, BDK and Keeling & Walker.
In partnering with both these companies, Codikoat's aim is to now produce a fully transparent adhesive film that, once administered, offers incredible sanitizing protection without interfering with the displays of touch screen devices. Keeling & Walker (https://www.keelingwalker.co.uk/) produces specialist pigments that form part of the protective coating for the adhesive film, while medical technology manufacturer BDK (https://www.bdk.uk.com/) delivers printing and production of the adhesive film.
CodiKoat's antimicrobial innovation, based on a hyper-durable coating nanotechnology that deactivates virus particles in seconds, can be used to treat heavily used public surfaces, such as ATM and fast-food self-service screens, which often play host to a staggering array of harmful viruses and bacteria, including E. coli and the coronavirus. Tests conducted by the Microbiology department at London Metropolitan University found that touchscreens in fast-food restaurants can carry traces of numerous harmful or unsanitary substances, and even staphylococcus, a bacterium that can cause blood poisoning and toxic shock syndrome.
From supermarket checkouts to public transport and even air travel, there is a growing reliance on self-service and touchscreen machines in our daily lives. These devices can be used thousands of times per day but even the most robust cleaning procedures in use today still rely on often-ineffective human intervention. Constant re-sanitization is a serious resource-drain for businesses, who could not possibly hope to clean the devices after every use.
CodiKoat has provided a solution to this, with its product being self-cleaning, durable, and offering the same outstanding ongoing protection for users no matter how frequently it's used. A prototype of the adhesive film product was previously tested at London's Royal Opera House, where a pilot scheme saw samples touched over 2 million times over three months, with no measurable drop in its antiviral capabilities.
During its development, CodiKoat underwent highly rigorous laboratory tests carried out at University College London under the supervision of the university's highly regarded Virology Research Services arm, on which the CodiKoat-treated acetate film was found to kill
Terry Pullen, CEO of GreenBank Capital, said: "We are understandably very excited about this latest development from CodiKoat. We saw great promise and a fantastic market opportunity for this young company and its management when we invested in the firm last year and have seen the efficacy and recognition for the public health potential of its product grow at significant pace and scale. We look forward to continuing to work closely with this incredibly innovative firm and moving its product into the next stage of its roll out."
- ENDS -
For further information, please contact:
PR Advisers:
Sapience Communications
James Gittings/Richard Morgan Evans
Email: Greenbank@sapiencecomms.co.uk
Tel: +44 (0)7308 509 608
About GreenBank
GreenBank is a next generation merchant banking business that has a flexible low-cost overhead structure designed to maximize profitability. Our management are based in Toronto, Dallas and London and are used to working across borders remotely. Our model of remote working, dynamic space and flexible contracts -rather than large, fixed costs - establishes GreenBank as a global merchant bank for the future, both during and after COVID19.
GreenBank is listed on the Canadian Securities Exchange, the Frankfurt Boerse and on the OTC Markets in the USA. GreenBank invests in undervalued exponential growth companies focused on building consistent capital appreciation for its shareholders.
SOURCE: GreenBank Capital Inc.
View source version on accesswire.com:
https://www.accesswire.com/694878/GreenBank-Capital-Portfolio-Company-CodiKoatDeliversRevolutionary-Biosafety-Product-and-Enters-Into-Partnerships
FAQ
What is the recent development by GreenBank Capital’s portfolio company CodiKoat?
Which companies partnered with CodiKoat for the new product?
How effective is CodiKoat’s antimicrobial product against viruses?
What is the significance of the adhesive film developed by CodiKoat?
What market opportunity does CodiKoat's product represent?
